P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN'S LYMPHOMA. (23rd June 2022) - Leabman, M. K.